Edgewise Therapeutics, Inc. Common Stock (EWTX) Stock Price
EWTXStock
$37.19+142.75%52W
Market Cap$4.04B
P/E—
PEG Ratio—
Div yield—
Beta0.39
EWTX Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)2.25%
Price vs S&P 500 (4W)-15.36%
VGM Score77.71
EWTX Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.47 | -$0.53 | -12.16%(-$0.06) | |
| Q1 2026 | -$0.48 | -$0.46 | +5.15%(+$0.02) | |
| Q4 2025 | -$0.44 | -$0.47 | -6.25%(-$0.03) | |
| Q3 2025 | -$0.40 | -$0.39 | +2.77%(+$0.01) | |
| Q2 2025 | -$0.42 | -$0.34 | +18.31%(+$0.08) |
EWTX Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.17
4.17
4.21
4.21
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
EWTXEdgewise Therapeutics, Inc. Common Stock | — | — | B | — | — | — | — | $37.19 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and cardiac conditions. Its lead candidate, Sevasemten, is an oral small molecule designed to address the root cause of dystrophinopathies, including Duchenne and Becker muscular dystrophy. The company is advancing additional product candidates targeting muscle disease across its pipeline.